ViroPharma Inc. has a Operating Profit Margin of 36.59%, a Earnings Per Share Growth Rate of 14.14%, a Current Ratio of 6.12, and a Quick Ratio of 5.57. The short interest was 13.45% as of 07/03/2012. ViroPharma Incorporated, a biotechnology company, develops and commercializes therapeutic products that address serious diseases in the United States and internationally. It focuses on developing products used by physician specialists or in hospital settings. The company markets and sells Cinryze, a C1 esterase inhibitor therapy for the routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema, a life-threatening genetic disorder; and Vancocin HCl capsule, an oral capsule formulation for the treatment of C. difficile-associated diarrhea (CDAD) and to treat enterocolitis caused by staphylococcus aureus, including methicillin-resistant strains.
Market Data 
Markets 
